Coronavirus Disease 2019 Hangover: A Rising Tide of Alcohol Use Disorder and Alcohol‐Associated Liver Disease

Abstract

The coronavirus disease 2019 (COVID‐19) pandemic has had a tremendous global impact since it began in November of 2019. However, there are concerns that the COVID‐19 pandemic will not affect all equally and that some populations will be particularly vulnerable. Relevant to liver disease, patients with alcohol use disorder (AUD) and alcohol‐associated liver disease (ALD) may be among the populations that are the most severely impacted. The reasons for this include being at a higher risk of severe COVID‐19 infection due to a depressed immune system and high‐risk underlying comorbidities, the injurious effect of COVID‐19 on the liver, the inability to attend regular visits with providers, diversion of hospital resources, and social isolation leading to psychological decompensation and increased drinking or relapse. As a result, we fear that there will be a dramatic rising tide of alcohol relapse, admissions for decompensated ALD, and an increase in newly diagnosed patients with AUD/ALD post–COVID‐19 pandemic. Providers and their institutions should implement preemptive strategies such as telehealth and aggressive patient outreach programs now to curb this anticipated problem. Liver transplantation (LT) centers should adapt to the pandemic by considering leniency to some LT candidates with ALD who cannot access appropriate alcohol treatment due to the current situation. In conclusion, the COVID‐19 pandemic will likely be especially detrimental to patients with AUD/ALD, and actions need to be taken now to limit the scope of this anticipated problem.

Practice Habits, Knowledge, and Attitudes of Hepatologists to Alcohol Use Disorder Medication: Sobering Gaps and Opportunities

“…Increasing the practice of AUD medication use is expected to become even more crucial in the coming months, considering the anticipated surge in AUD and ALD instigated by the COVID-19 pandemic. 24 …”

Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic

“…Patients should be made aware of potential adverse metabolic and hepatic consequences of social isolation, including Alcohol-related liver disease Chronic alcohol consumption may increase an individual's susceptibility to acute respiratory distress syndrome secondary to SARS-CoV-2 infection. 56 Social isolation can lead to new or increased alcohol consumption 57 ; an increase in alcohol-related admissions including new hepatic decompensation should be anticipated during and after periods of physical distancing. Clinicians and institutions should therefore implement preemptive strategies such as patient outreach and telephone alcohol liaison and cessation services.…”

Chronic Liver Disease and COVID‐19: Alcohol Use Disorder/Alcohol‐Associated Liver Disease, Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Autoimmune Liver Disease, and Compensated Cirrhosis

“…Furthermore, the immunosuppressive effects of corticosteroid therapy for alcoholic hepatitis, as well as AUD itself, are risk factors for severe disease 5 . Although there is no specific guidance on management of alcoholic hepatitis during the COVID‐19 pandemic, caution is advised regarding glucocorticoids therapy in SARS‐CoV‐2 infection 5,6 . The pandemic has also raised significant barriers for patients with AUD being considered for liver transplantation, resulting in both increased risk for relapse and difficulties in maintaining linkage to care 5 …”